Research and Markets: With Successful Life-Cycle Management, Bayer's Established Products Levitra, Kogenate, Trasylol and Avalox Continue to Drive Sales.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c37461) has announced the addition of the Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. report "Bayer Pharmaceutical Company Intelligence Report" to their offering Bayer is a global enterprise, headquartered in Germany, with core competencies A core competency is something that a firm can do well and that meets the following three conditions specified by Hamel and Prahalad (1990):
A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. for key products to 2010. Bayer currently ranks 15th among research-based pharmaceutical companies in terms of pharma sales and annually invests about 7.1 per cent of its total sales in research and development, ranking 74th compared to other pharmaceutical companies. Oncology and cardiovascular risk management, including diabetes, are the main areas of Bayer's future strategic focus within pharmaceuticals. Current Growth Drivers With successful life-cycle management, the established products Levitra, Kogenate, Trasylol and Avalox continue to drive sales. Key Late-Phase Products Reaching the Market Place Nexavar was launched for renal cell carcinoma renal cell carcinoma or hypernephroma Malignant tumour of the cells that cover and line the kidney. It usually affects persons over age 50 who have vascular disorders of the kidneys. It seldom causes pain, unless it is advanced. in the US in December 2005, and an EU launch is expected in the second half of 2006. A Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA trial in hepatocellular carcinoma hep·a·to·cel·lu·lar carcinoma n. A carcinoma derived from parenchymal cells of the liver. Also called hepatocarcinoma, malignant hepatoma. started in March 2005, is now completed. Key Late-Stage Products BAY 59-7939, an oral, direct inhibitor of Factor Xa, is currently in Phase III development for venous thromboembolism thromboembolism /throm·bo·em·bo·lism/ (-em´bo-lizm) obstruction of a blood vessel with thrombotic material carried by the blood from the site of origin to plug another vessel. throm·bo·em·bo·lism n. (VTE VTE Vocational and Technical Education VTE Venous Thrombo Embolism VTE Vacuum Thermal Evaporation VTE Vientiane, Laos - Wattay (Airport Code) VTE Virtual Terminal Environment VTE Video Transfer Engine VTE Video Tape Editing ) prevention after major orthopaedic surgery has been initiated. The product is on schedule for regulatory filing in late 2007. This company report provides: Latest Results A brief review of the latest report results Executive Summary At a glance understanding of the major trends and events affecting the company Financial Analysis (current year) Detailed P&L and investment review of the latest full year performance Company Strategy Where's the company going and how does it plan getting there? Product/R&D Pipeline Highly detailed monographs organised by therapeutic category. Also covers R&D strategy/pipeline and provides 5-year sales forecasts to 2010 for major launched products where available Appendices ap·pen·di·ces n. A plural of appendix. 5-year financial assessment Key corporate events Key agreements Infrastructure Major pharmaceutical subsidiaries/joint ventures Product index Companies Mentioned Include: --Actimis Pharmaceuticals --Asklepios Biopharmaceutical Inc --Bausch & Lomb --Boehringer Ingelheim --Bristol-Myers-Squibb --CuraGen Corporation --deCODE genetics --First Horizon Pharmaceutical Corporation --GlaxoSmithKline --GW Pharmaceuticals plc --Johnson & Johnson --Medicines for Malaria Venture (MMV MMV Medicines for Malaria Venture MMV Multimedia Victoria mmv Met Medewerking Van (Dutch: with the Cooperation Of) MMV Mobile Money Ventures, LLC (joint venture of SK Telecom and Citigroup) ) --Memory Pharmaceuticals Inc --Millennium Pharmaceuticals Inc --Nektar Therapeutics Corporation --Novartis Pharma GmbH --Nuvelo Inc --Onyx Pharmaceuticals Inc --Ranbaxy Laboratories Limited --Remedyne Corporation --Schering-Plough --Shionogi --Ventiv Health Inc --World Heart Federation --Zilip-Pharma For more information visit http://www.researchandmarkets.com/reports/c37461 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion